SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) has been given an average rating of “Moderate Buy” by the ten ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to [...]